ASA - Angelman Syndrome Alliance

Routebeschrijving Website Contact opnemen met de organisatie

ASA - Angelman Syndrome Alliance A global collaboration of independent Angelman organisations. Research powered by parents. Please do get in contact if you are interested in membership.

The Angelman Syndrome Alliance – Manifesto

Pioneers in scientific research
The Angelman Syndrome Alliance (ASA) is a partnership of organizations from around the world that are focused on supporting people with Angelman Syndrome, their loved ones, carers and clinicians. By combining resources, knowledge and a relentless dedication to initiate change, the ASA is uniquely positioned to drive advances in scientific knowledge about Angelman Syndrome. As a rare disease, funding for scientific research from major funders is limited. The ASA is breaking new ground, utilizing limited resources from around the globe in a smarter manner. By combining financial resources we can fund research that individually our organisations could not. The ASA is registered in the Netherlands at the Chamber of Commerce under the number 75110830 with the RSIN number 860146583

The post address of the ASA is:
Proveniersstraat 5b
3033 CE ROTTERDAM
Netherlands

ASA Board

Betty Willemsen - President of ASA
Peter Sel - Vice-President of ASA
Manuel Trocado Costa Duarte - Treasurer of ASA


The Scientific Advisory Board (SAB)

Professor Hanoch Kaphzan, University of Haifa
Professor Martin Scheffner, University of Konstanz
Professor Harald Sitte, Medical University of Vienna

The role of the SAB is to oversee the review of grant applications, and to offer advice and guidance to the ASA Board and ASA members. ASA Members

The members contribute funds to the research grants provided by the Angelman Syndrome Alliance. Many other organisations attend our annual meetings and contribute through suggestions and guidance. ASA Associates

Parent organizations that want to become a full member but do not have the necessary means yet, are welcome as Associate members. As an associate you inform interested parties in your country about ASA projects (AS parents, therapists, doctors and scientist ), you to make a list of all important Angelman Syndrome researchers in your country and send it to the scientific board of ASA, and you make a noticeable effort to gather funding so you can participate as a full ASA member in the next round (which is every 2 years, so 2016-2018-2020 and so on). In every country there can be only one parent organization as a representant within ASA. All of the funds gathered by the ASA are going to our cause, this means that all the people that work for the ASA do so on a pro deo basis, they receive no salary or compensation other than the feeling of knowing they contributed to our cause.

08/09/2026

When people hear the words "rare disease", they often think of something that touches very few people. The reality is different.

A rare disease is a condition experienced by fewer than 1 in 2,000 people. Yet, with more than 6,000 known rare diseases, they are part of the lives of over 300 million people worldwide.

Behind these numbers are people and families navigating delayed diagnoses, limited treatment options, fragmented care, isolation and other everyday challenges that often go unseen.

Rare diseases are rare.
People living with them are not.

💚 Learn more at: https://go.eurordis.org/whatisararedisease

For those who may not yet be aware, Ultragenyx shared a press release (attached) announcing the results of their Phase 3...
05/09/2026

For those who may not yet be aware, Ultragenyx shared a press release (attached) announcing the results of their Phase 3 ASPIRE trial.

We know that these results are deeply disappointing for our community. Many families have followed the development of this treatment with hope, and we recognise the emotions that this news may bring.

At ASA, we believe it is important to share information openly and honestly, while also supporting our families as they navigate what these results mean. The outcome of one clinical trial does not diminish the importance of the progress that has been made in Angelman syndrome research, nor does it define the future of our field.

Our community has shown time and again how resilient, determined and united it can be. We remain firmly committed to supporting and funding basic research, and to working alongside researchers, clinicians and our partners to advance our understanding of Angelman syndrome and develop better outcomes for our families.

There is still much to learn, and much work to be done. We will continue moving forward together, with determination and hope.

04/06/2026

The Angelman Syndrome Alliance (ASA) is proud to announce the recipients of its 2026 Scientific Research Grants. This year’s call for proposals attracted exceptionally high-quality research projec…

10 years ago this weekend, Angelman UK hosted the 4th ASA - Angelman Syndrome Alliance scientific conference in Liverpoo...
05/10/2025

10 years ago this weekend, Angelman UK hosted the 4th ASA - Angelman Syndrome Alliance scientific conference in Liverpool, England, as well as a gala in recognition of what would have been Harry Angelman’s 100th birthday! Families heard about Angelman research from international scientists, and were entertained in the evening by our patron Gareth Edwards, along with relatives of Harry Angelman. Such an amazing & memorable weekend!

⏰ Final Call – ASA Grant 2026The deadline for our 6th international scientific grant call is November 1, 2025.This grant...
30/09/2025

⏰ Final Call – ASA Grant 2026

The deadline for our 6th international scientific grant call is November 1, 2025.

This grant exists because of you — families and friends across the world who united to raise funds for Angelman Syndrome research.

Now we ask for your help one more time:
👉 Please share the grant call with scientists and research teams.
👉 Spread the word in your networks.
👉 Help us reach every researcher who could make a difference.

Together, we can ensure the brightest minds apply and move us closer to treatments. 🌍✨

🔗 Full details & how to apply: angelmanalliance.org/asa-2026

Today, representatives from 11 international Angelman syndrome organisations met to discuss future priorities for  - Ang...
27/09/2025

Today, representatives from 11 international Angelman syndrome organisations met to discuss future priorities for - Angelman syndrome alliance. Thank you Conny & e.V for hosting the meeting in Hamburg.

Together we are stronger.

ASA - Angelman Syndrome Alliance Angel - Associação Síndrome de Angelman Portugal Association Française du Syndrome d'Angelman Angelman Syndrome Ireland ORSA Organizzazione Sindrome di Angelman Asociace genové terapie, z.s. A.S.A. ASOCIACION SINDROME DE ANGELMAN - ESPAÑA Angelman e.V. Angelman Syndroom NL Angelman UK Mizukawa Masako Angelman Verein Österreich

www.angelmanalliance.org

💙 Angelman Syndrome Phase 3 Trials – Community Update 💙Earlier this month, Foundation for Angelman Syndrome Therapeutics...
18/09/2025

💙 Angelman Syndrome Phase 3 Trials – Community Update 💙

Earlier this month, Foundation for Angelman Syndrome Therapeutics and ASA - Angelman Syndrome Alliance co-hosted a community webinar to share updates on the ongoing Phase 3 trials for Ultragenyx (GTX-102) and Ionis (ION-582).

Families will find practical information on study designs, age groups, timelines, and what participation in a trial may involve.

❗️Every child and family is unique. Clinical trials are still evaluating investigational medicines, and participation is a deeply personal decision. Please discuss any questions with your doctor or medical team before considering enrollment.

You can read more about it ⬇️.
https://angelmanalliance.org/community-update-phase-3-trials-ultragenyx-ionis/

📺 You can watch the full webinar here: https://youtu.be/TenTbLp9pIk

ANGELMAN SYNDROME PHASE 3 TRIALS — COMMUNITY UPDATE (Webinar recorded: 4 Sep 2025)WHO HOSTED• FAST (Foundation for Angelman Syndrome Therapeutics): \$60M+ in...

Families in Europe and UK. 🇪🇺🇬🇧Angelman Syndrome Phase 3 Clinical Trial Update - Europe & UK. Join ASA - Angelman Syndro...
15/07/2025

Families in Europe and UK. 🇪🇺🇬🇧

Angelman Syndrome Phase 3 Clinical Trial Update - Europe & UK.

Join ASA - Angelman Syndrome Alliance and Foundation for Angelman Syndrome Therapeutics for a live webinar focused on Phase 3 clinical trials in Europe and U.K.

📅 Thursday 4th September 2025.

⏰ 8.00-9.00 pm (+2.00 Paris).

Representatives from Ionis and Ultragenyx will share details about their trials, including:
· Clinical trial design
· Inclusion and exclusion criteria
· Locations of trial sites across Europe and the UK
· What steps families can take if interested in participating

· URL: http://bit.ly/angelman-webinar

Link for calendar: https://www.addevent.com/event/Pg2602874

💙 We’re proud to announce our 6th ASA Research Grant Call! 💙 Thanks to the generosity and unwavering commitment of our m...
01/06/2025

💙 We’re proud to announce our 6th ASA Research Grant Call! 💙

Thanks to the generosity and unwavering commitment of our member organisations, families, and supporters, the Angelman Syndrome Alliance (ASA) is once again able to fund research into Angelman Syndrome.

Your contributions are making a difference — helping us get one step closer to answers for our children and loved ones.

🔬 The ASA 2026 Scientific Grant Call is now open to researchers around the world. We’re offering up to €120,000 for fundamental and translational research projects that aim to deepen understanding of Angelman Syndrome and pave the way toward new treatments.

🧠 Topics may include:
🔹 UBE3A biomarkers
🔹 Clinical outcome tools
🔹 Neuronal phenotyping
🔹 Preclinical models — and more

📅 Deadline for proposals: November 1, 2025
📌 Apply now: https://angelmanalliance.org/grant-application-asa-grant-2026

Let’s keep pushing forward — together.
Thank you for believing in the power of science, and in a better future for our community. 💫

Exciting news! In October 2024, ASA became an official member of EURORDIS-Rare Diseases Europe, the European federation ...
22/01/2025

Exciting news! In October 2024, ASA became an official member of EURORDIS-Rare Diseases Europe, the European federation of rare disease patient organisations. EURORDIS has been the voice of rare disease patients, empowering, advocating for and engaging patients for over 25 years, helping to raise the patient perspective in Europe. This membership can help YOU as an ASA member to learn more about advocating for Angelman syndrome at the local, national and international level....

Exciting news! In October 2024, ASA became an official member of EURORDIS-Rare Diseases Europe, the European federation of rare disease patient organisations. EURORDIS has been the voice of rare d…

Adres

Proveniersstraat 5b
Rotterdam
3033CE

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer ASA - Angelman Syndrome Alliance nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Contact Opnemen Met De Organisatie

Stuur een bericht naar ASA - Angelman Syndrome Alliance:

Snelkoppelingen

Delen